Drugs that contain Ibrexafungerp Citrate

1. List of Brexafemme drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

NCE-1 date: June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in